Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Clearmind Medicine (CMND)

Clearmind Medicine Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CMND
DateTimeSourceHeadlineSymbolCompany
16/12/202413:37GlobeNewswire Inc.Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystalâ„¢ FormatNASDAQ:CMNDClearmind Medicine Inc
09/12/202422:12Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CMNDClearmind Medicine Inc
06/12/202422:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
20/11/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
10/10/202420:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
10/10/202412:07GlobeNewswire Inc.Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical SiteNASDAQ:CMNDClearmind Medicine Inc
01/10/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CMNDClearmind Medicine Inc
26/09/202420:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
24/09/202420:30Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:CMNDClearmind Medicine Inc
16/09/202420:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
16/09/202420:06GlobeNewswire Inc.Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination TherapyNASDAQ:CMNDClearmind Medicine Inc
16/09/202420:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
12/09/202420:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
12/09/202412:20GlobeNewswire Inc.Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD TreatmentNASDAQ:CMNDClearmind Medicine Inc
06/09/202420:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
06/09/202411:55GlobeNewswire Inc.Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination TreatmentNASDAQ:CMNDClearmind Medicine Inc
06/09/202411:55GlobeNewswire Inc.SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination TreatmentNASDAQ:CMNDClearmind Medicine Inc
29/08/202420:25GlobeNewswire Inc.Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination TreatmentNASDAQ:CMNDClearmind Medicine Inc
21/08/202420:11GlobeNewswire Inc.Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior TreatmentNASDAQ:CMNDClearmind Medicine Inc
16/08/202420:14GlobeNewswire Inc.Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental DisordersNASDAQ:CMNDClearmind Medicine Inc
06/08/202412:57GlobeNewswire Inc.Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss DrugNASDAQ:CMNDClearmind Medicine Inc
06/08/202412:57GlobeNewswire Inc.SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss DrugNASDAQ:CMNDClearmind Medicine Inc
31/07/202411:44GlobeNewswire Inc.Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking ResearchNASDAQ:CMNDClearmind Medicine Inc
19/07/202411:55GlobeNewswire Inc.Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage ProductNASDAQ:CMNDClearmind Medicine Inc
16/07/202413:02GlobeNewswire Inc.Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for AlcoholismNASDAQ:CMNDClearmind Medicine Inc
16/07/202410:03GlobeNewswire Inc.SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight LossNASDAQ:CMNDClearmind Medicine Inc
16/07/202410:03GlobeNewswire Inc.Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-lossNASDAQ:CMNDClearmind Medicine Inc
12/07/202412:02GlobeNewswire Inc.Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 ConferenceNASDAQ:CMNDClearmind Medicine Inc
28/06/202411:55GlobeNewswire Inc.Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors TreatmentNASDAQ:CMNDClearmind Medicine Inc
20/06/202411:57GlobeNewswire Inc.Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD TreatmentNASDAQ:CMNDClearmind Medicine Inc
 Showing the most relevant articles for your search:NASDAQ:CMND